Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19, Topics Feb 05 | 2021Liso-cel Approved by FDA as BreyanziAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Feb 05 | 2021Yescarta’s Q4 2020 Sales Decline and Kymriah Takes a QoQ Sales Lead for the First Time; Gilead Q4 2020 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 04 | 2021No Regulatory Updates for Liso-cel; Orva-cel Discontinued; BMS Q4 2020 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Feb 01 | 2021JNJ / Legend Granted EU Accelerated Assessment for Cilta-cel; Can Cilta-cel's MAA Submission Occur Before March 8, 2021?Access Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19, CD22 Jan 30 | 2021Thoughts on Autolus Suitors for AUTO3Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Jan 26 | 2021Could Kymriah Have Become the CAR-T Market Leader in Q4 2020? PORTIA Deprioritized; No Updates on Cilta-cel’s Regulatory Submissions; Novartis and JNJ Q4 2020 Earnings Call SummariesAccess Free Blast
Free
Posted in: BCMA, CAR-T Jan 25 | 2021CHMP Agenda Includes Hidden Request for Cilta-cel Accelerated Assessment; Precision Issued with a Notice of Allowance for PBCAR19B's PatentAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 22 | 2021Yescarta Approved in Japan; Early Reimbursement Likely by March; UPDATED: Indications Table for CD19 CAR-T US Approvals and SubmissionsAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Jan 21 | 2021Thoughts on Gracell's NMPA Accepted IND for GC019F a Rapidly Manufactured CD19 CAR-TAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 20 | 2021NICE Recommends Tecartus in MCL; First Full Access Deal for Tecartus in EuropeAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Jan 20 | 2021FDA Accepts Precision's PBCAR19B IND in R/R NHL; Francesco Marincola Joins Kite as Worldwide Head of Cell Therapy ResearchAccess Free Blast
Free
Posted in: Autologous, CAR-T Jan 15 | 2021New Legend Ph1 Trial for CD4 CAR-T (LB1901) in R/R T-Cell Lymphoma PostedAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, TCR Jan 14 | 2021JPM 2021 Day 4: Legend Biotech, Precision BioSciences, and ZiopharmAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 13 | 2021JPM 2021 Day 3: Allogene, Autolus, and TmunityAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 12 | 2021JPM 2021 Day 2: Gilead and SpringWorksAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, NVS Jan 11 | 2021JPM 2021 Day 1: BMS, bluebird bio, Novartis, and JNJAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 01 | 2021Celgene’s CVR Payment Vanishes As Liso-cel Is Not Approved Before Dec 31, 2020Access Free Blast
Free
Posted in: BCMA, CAR-T Dec 21 | 2020Cilta-cel Submitted in US; Could Approval be Earlier than August 2021?Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Dec 16 | 2020The EC Grants Tecartus Conditional Marketing Authorization for r/r MCL; UPDATED: US CAR-T Approvals TableAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Dec 16 | 2020Thoughts on Bayer’s and Atara’s Collaboration to Develop Solid Tumor CAR-T TherapiesAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.